Last reviewed · How we verify
TNM001
TNM001 is a trispecific antibody that simultaneously engages multiple immune checkpoints to enhance anti-tumor T-cell responses.
TNM001 is a trispecific antibody that simultaneously engages multiple immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | TNM001 |
|---|---|
| Sponsor | Zhuhai Trinomab Pharmaceutical Co., Ltd. |
| Drug class | Trispecific monoclonal antibody |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TNM001 is designed as a trispecific monoclonal antibody that targets multiple immune regulatory pathways simultaneously. By engaging three distinct molecular targets on immune cells and/or tumor cells, it aims to overcome immune suppression more effectively than bispecific or monospecific approaches, potentially enhancing T-cell activation and proliferation against cancer cells.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants (PHASE3)
- A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants (PHASE2, PHASE3)
- A Study of TNM001 in Chinese Healthy Preterm and Term Infants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNM001 CI brief — competitive landscape report
- TNM001 updates RSS · CI watch RSS
- Zhuhai Trinomab Pharmaceutical Co., Ltd. portfolio CI